Inmagene Biopharmaceuticals

Inmagene Biopharmaceuticals (now ImageneBio, Nasdaq: IMA) is a verified clinical-stage biotechnology company developing novel therapeutics like IMG-007 for immunological diseases. While the project demonstrates high real-world utility and technical innovation with over $175M in historical funding and active Phase 2 trials, the submission itself was of extremely poor quality, containing false claims about user reach ('everyone') and traction ('most people have used my product'). The score reflects the legitimate high-value nature of the pharmaceutical assets and public market status, significantly adjusted for the discrepancy between the professional entity and the low-effort submission.